Chronic kidney disease (CKD) has been associated with increased cardiovascular risk. Conventional echocardiographic indices and novel 2D speckle tracking (2DST), deformation related indices, are considered to be a suitable diagnostic utility for the evaluation of subclinical left ventricular (LV) dysfunction and may discriminate patients at high cardiovascular related risk. The aim of the study was to identify differences between CKD patients and healthy controls, using classical and novel 2DST echocardiographic indices, after dypiridamole infusion. METHODS: Thirty CKD patients (mean eGFR 34.7617.6ml/min/1.73m 2 ,urine protein median value 1010 mg/24hr, mean age 54 years old, 70% men), in steady state from the outpatient clinic and 15 age and gender matched healthy controls (mean age 50 years old, 67% men) were included in this prospective study. Exclusion criterion was known cardiovascular disease. LV systolic and diastolic function indices (by conventional tissue Doppler and 2DST echocardiography) were assessed at baseline and after administration of dipyridamole in all subjects. Coronary flow reserve (CFR), on LAD was also assessed. RESULTS: CKD patients had higher MPI (0.5560.13 vs 0.4460.15) and E/E' (7.762.1 vs 6.161.5) values (p<0.05 for all) compared to controls. CFR values after dipyridamole administration were lower in CKD compared to controls [median value 3.3 (2.5, 3.5) vs 3.9 (3.0, 4.5), p¼0.037]. Dipyridamole use caused an increase in E and A wave, MAPSE septal and lateral and a decrease in global longitudinal and global circumferential strain in both CKD patients and controls (p<0.05 for all). On the other hand E/A, MPI, E/Vp and time to untwist were decreased only in CKD patients while DecT was decreased only in controls (p<0.05 for all) after dipyridamole administration. Only dipyridamole-induced changes in DecT were different between CKD and controls (p¼0.039). CONCLUSIONS: Compared to age-and gender-matched healthy controls, CKD patients had worse microvascular coronary function (decreased CFR) and impaired indices of diastolic function. Dipyridamole administration caused similar changes in novel and classical indices of heart function in both groups. DecT, an index of diastolic heart function, was decreased after dipyridamole only in controls but not in CKD patients.
INTRODUCTION AND AIMS:
Chronic kidney disease (CKD) has been associated with increased cardiovascular risk. Conventional echocardiographic indices and novel 2D speckle tracking (2DST), deformation related indices, are considered to be a suitable diagnostic utility for the evaluation of subclinical left ventricular (LV) dysfunction and may discriminate patients at high cardiovascular related risk. The aim of the study was to identify differences between CKD patients and healthy controls, using classical and novel 2DST echocardiographic indices, after dypiridamole infusion. METHODS: Thirty CKD patients (mean eGFR 34.7617.6ml/min/1.73m 2 ,urine protein median value 1010 mg/24hr, mean age 54 years old, 70% men), in steady state from the outpatient clinic and 15 age and gender matched healthy controls (mean age 50 years old, 67% men) were included in this prospective study. Exclusion criterion was known cardiovascular disease. LV systolic and diastolic function indices (by conventional tissue Doppler and 2DST echocardiography) were assessed at baseline and after administration of dipyridamole in all subjects. Coronary flow reserve (CFR), on LAD was also assessed. RESULTS: CKD patients had higher MPI (0.5560.13 vs 0.4460.15) and E/E' (7.762.1 vs 6.161.5) values (p<0.05 for all) compared to controls. CFR values after dipyridamole administration were lower in CKD compared to controls [median value 3.3 (2.5, 3.5) vs 3.9 (3.0, 4.5), p¼0.037]. Dipyridamole use caused an increase in E and A wave, MAPSE septal and lateral and a decrease in global longitudinal and global circumferential strain in both CKD patients and controls (p<0.05 for all). On the other hand E/A, MPI, E/Vp and time to untwist were decreased only in CKD patients while DecT was decreased only in controls (p<0.05 for all) after dipyridamole administration. Only dipyridamole-induced changes in DecT were different between CKD and controls (p¼0.039). CONCLUSIONS: Compared to age-and gender-matched healthy controls, CKD patients had worse microvascular coronary function (decreased CFR) and impaired indices of diastolic function. Dipyridamole administration caused similar changes in novel and classical indices of heart function in both groups. DecT, an index of diastolic heart function, was decreased after dipyridamole only in controls but not in CKD patients.
SP255 CKD PATIENTS WITHOUT SIGNIFICANT PROTEINURIA -WHAT ARE THE RISK FACTORS FOR PROGRESSIVE RENAL DISEASE?
Hiroshi Tanaka   1   1 Internal Medicine/Nephrology, Mihara Red Cross Hospital, Mihara, Japan INTRODUCTION AND AIMS: CKD patients without significant proteinuria are largely considered to have their eGFR decline slower than proteinuric patients have. Nevertheless many of those patients have progressive renal diseases, often eventually reaching ESRD. Little is known about prognostic factors of CKD in patients without significant proteinuria. The purpose of this study is to discriminate high-risk CKD patients, especially in populations without significant proteinuria. METHODS: As a hospital-wide survey, a whole set of laboratory tests were retrieved over 26 months (from October 2015 to December 2017 . Patients with at least 3 measurements of eGFR over more than 365 days, with an averaged eGFR of less than 50 mL/ min/1.73m2, were collected; then an eGFR slope was calculated for each patient. For the assessment of proteinuria, a dipstick urine protein determination was considered to better represent the real-world clinics for all the subspecialities in the Hospital; numbers of 0, 0.5, 1, 2, 3 or 4 were applied to (-), (þ-), (1þ), (2þ), (3þ) or (4þ) respectively, then the numbers were averaged during the study period (avUprot); urinalysis was done on an average of 8. RESULTS: This study showed a highly significant increase of serum Angiopioetine-2 level in CKD patients compared to control group, and significantly increase in group 2 (CKD patients on regular HD) compared to group I(CKD patients stage3-4).And there was a highly significant positive correlation between Angiopioetine-2 , Hs CRP and CIMT in CKD patients. And there were a highly significant positive correlation between Angiopioetine-2 and total cholesterol ,triglyceride, low density lipoprotein while there were a highly significant negative correlation between Angiopioetine-2 and high density lipoprotein in both group patients. CONCLUSIONS: The study concluded that increase serum level of Angiopoietin-2 in CKD patients and it had role as inflammatory marker and early detection of atherosclerosis. These results indicated that elevated serum marker of inflammation as Angiopoietin -2 is associated with increased risk of cardio vascular affection in end stage renal disease patient resulting in increased morbidity and mortality. So we recommended Ang-2 blockade may represent a novel therapy for cardiovascular protection in CKD.
SP257 EARLY RENAL INFLAMMATORY MOLECULE EXPRESSION DIFFERENCES AFTER UNILATERAL URETER OBSTRUCTION IN MICE
Gabor Kokeny
INTRODUCTION AND AIMS:
We have recently shown strain dependent renal fibrosis progression after unilateral ureter obstruction (UUO) in C57Bl6/J (B6) and CBA mouse strains (Mozes et al, Nephrol Dial Transplant 2017; 32 (S3): iii559). Although renal complement expression has been described in several experimental and human kidney diseases, little is known about early (less then 1 day) renal events after UUO. Thus, we investigated whether renal expression of inflammatory molecules depend on genetic variability of mice at 6 hours after UUO.
METHODS:
The left ureter of male B6 and CBA mice was proximally ligated (UUO) under anesthesia. Kidneys were harvested 6 hours after surgery (n¼5/strain) and gene expression pattern of whole kidney homogenates was investigated using qPCR. 
INTRODUCTION AND AIMS:
Renal dysfunction, hypertension (HT) and rheumatoid arthritis (RA) are associated with higher risk for cardiovascular mortality. Additional risk factors -endothelial dysfunction, insulin resistance, adipose tissue exchange disorders may play important role in this risk formation. We aimed to evaluate endothelial function, insulin resistance, adiponectin level in hypertensive females with renal dysfunction and comorbid RA. METHODS: 69 hypertensive females with renal dysfunction and comorbid RA (mean age -54 [50,3; 61,5] years) were enrolled. Control subgroup made hypertensive RA females without renal dysfunction (n¼31). All patients received stable therapy more than 6 months. The levels of adiponectin, insulin were measured using ELISA kit test, insulin resistance was estimated using HOMA2 index. Endothelial-dependent flow mediated vasodilatation (EDVD) by D. Celermajer method and carotid ultrasound were performed. Statistical analysis included non-parametric methods with p value < 0.05. RESULTS: Subclinical manifestations of atherosclerosis were established in 88.2% hypertensive females with renal dysfunction and RA and 40% control group pts with comparable risk factors. 10-year risk of fatal cardiovascular events matched by SCORE was 2.78 [2.06; 3.11] %. Endothelial dysfunction was established in the majority of patients of main group -31 (73.8%), insulin resistance -in 35 (83.3%), elevated levels of adiponectin -in 18 (42.9%). Hypertensive renal dysfunction females with RA had significantly higher adiponectin, insulin, insulin resistance levels compare to control (p<0.05). The presence of atherosclerotic plaques in hypertensive renal dysfunction females with RA was associated with age (OR¼1,124, h¼0,024, 95% CI 1,07-1,23), RA disease activity (OR¼1, 325, h¼0, 004, 95% CI 1, 45), endothelial dysfunction (OR¼1, 578, h¼0, 001, 95% CI 1, 73), insulin resistance (OR¼1, 678, h¼0, 014, 95% CI 1, 84), abnormal adiponectin level (OR¼1, 227, h¼0, 028, 95% CI 1, 43) . CONCLUSIONS: Females with renal dysfunction comorbid with rheumatoid arthritis are characterized by high frequency of endothelial dysfunction, insulin resistance, adipose tissue disorders and frequency of subclinical atherosclerosis do not fully reflected by SCORE.
SP259 IRON DEFICIENCY AND FGF 23 IN CHRONIC KIDNEY DISEASE

Insa Emrich
INTRODUCTION AND AIMS: Chronic kidney disease patients are affected by a high burden of cardiovascular morbidity and mortality. Chronic kidney disease -mineral and bone disorder (CKD-MBD) with high levels of intact FGF23 and c-terminal FGF23 may contribute to this elevated cardiovascular risk. Recently, it has been shown that iron deficiency, which is very prevalent in CKD patients, up-regulates plasma FGF23. We now hypothesize that iron deficiency rather than direct FGF23 effects pathophysiologically explains the high cardiovascular event rate among CKD patients with highest plasma FGF23 levels. Therefore we investigated in the following the independent contribution of plasma intact FGF23, c-terminal FGF23 and ferritin on cardiovascular morbidity in CKD patients . METHODS: In the ongoing CARE FOR HOMe study which recruited CKD KDIGO stages G2 to G4 patients, we analyzed ferritin, intact FGF23 and c-terminal FGF23 at baseline. The participants were consecutively followed annually for the occurrence of atherosclerotic cardiovascular events and all-cause mortality.
RESULTS: Ferritin correlated negatively with c-terminal FGF23 (r ¼ -0.207; p ¼ < 0.001) but not with intact FGF23 (r ¼ -0.016; p ¼ 0.699). Participants in KDIGO stage G4 and ferritin levels lower than 30 ng/ml had the highest c-terminal FGF23 levels. During follow up of 5.1 6 2.1 years, 123 had atherosclerotic cardiovascular events, and 98 participants died from any cause, in multivariate Cox regression analyses after adjustment for multiple confounders (including ferritin and intact FGF-23), only c-terminal FGF23 remained significantly associated with cardiovascular events all-cause death. In contrast, neither intact FGF23 nor ferritin predicted adverse outcome in multivariate analyses. CONCLUSIONS: In this study, we observed a close correlation between iron deficiency -indicated by low plasma ferritin -and c-terminal FGF23 among CKD patients. C-terminal FGF23 was independently associated significantly with all-cause mortality even after adjustment for ferritin and other confounders, whereas ferritin did not predict cardiovascular events.
SP260 P53 PROMOTES HYPOXIA INDUCED RENAL TUBULAR EPITHELIAL CELL G2/M ARREST AND RENAL FIBROSIS
Shiren Sun
INTRODUCTION AND AIMS: Dyslipidemia and oxidative stress are common cardiovascular disease (CVD) risk factors in end-stage renal disease (ESRD). ESRD patients on hemodialysis (HD) usually present normal or decreased total cholesterol (TC) and low-density lipoprotein cholesterol (LDLc), decreased high-density lipoprotein cholesterol (HDLc) and increased triglycerides (TG). Oxidation of LDL (oxLDL) is a triggering factor for initiation and progression of atherosclerosis. Recent data showed that LDL is a heterogeneous population of particles with different atherogenic properties. It was hypothesized that LDL quality (size and composition) may be a more important risk factor than its levels. Small and denser LDL subpopulations are more atherogenic
